Influence of a stearic acid-rich structured triacylglycerol on postprandial lipemia, factor VII concentrations, and fibrinolytic activity in healthy subjects.
BACKGROUND
An elevated postprandial lipid concentration is believed to be atherogenic and to increase the risk of thrombosis.


OBJECTIVE
The objective was to test whether the consumption of a stearic acid-rich structured triacylglycerol has adverse effects on postprandial fibrinolytic activity and lipemia, factor VII coagulant (FVII:c) activity, and activated FVII (FVIIa) concentrations.


METHODS
A randomized crossover design was used to compare the effects on middle-aged healthy men (n = 17) and women (n = 18) of meals enriched with cocoa butter, high-oleate sunflower oil (oleate), or a structured triacylglycerol containing stearic acid.


RESULTS
The mean increases from fasting in plasma triacylglycerol 3 h after the oleate, cocoa butter, and structured triacylglycerol meals were 1.36 (95% CI: 1.17, 1.56), 1.39 (1.17,1.63), and 0.65 (0.50, 0.82) mmol/L, respectively. Tissue plasminogen activator activity increased and plasminogen activator type 1 activity decreased after all 3 meals. Plasma FVII:c increased after the oleate and cocoa butter meals but not after the structured triacylglycerol meal. The values 6 h after the oleate and cocoa butter meals were 11.3% (7.0%, 15.6%) and 9.9% (4.7%, 15.2%), respectively, and were significantly different (P < 0.0001 and P = 0.001, respectively) from the value after the triacylglycerol meal [2.1% (-1.1%, 5.3%)]. Plasma FVIIa increased after all 3 meals, more so after the oleate and cocoa butter meals than after the structured triacylglycerol meal.


CONCLUSIONS
The consumption of stearic acid in the form of a structured triacylglycerol leads to less of an increase in plasma triacylglycerol and in FVII:c than does a meal enriched in cocoa butter or oleate.
Nutrition Food and Health Research Centre, King's College London, London, Unted Kingdom. tom.sanders@kcl.ac.uk
T A
TA
Sanders
F R
FR
Oakley
J A
JA
Cooper
G J
GJ
Miller
D000328:Adult; D018592:Cross-Over Studies; D004041:Dietary Fats / Q000008:administration & dosage; D005167:Factor VII / Q000378:metabolism*; D015942:Factor VIIa / Q000378:metabolism; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis; D005344:Fibrinopeptide A / Q000378:metabolism; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D019301:Oleic Acid / Q000008:administration & dosage; D019518:Postprandial Period; D012307:Risk Factors; D013229:Stearic Acids / Q000008:administration & dosage*; D013927:Thrombosis / Q000517:prevention & control; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D014280:Triglycerides / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry
D004041:Dietary Fats; D008055:Lipids; D013229:Stearic Acids; D014280:Triglycerides; D005344:Fibrinopeptide A; D019301:Oleic Acid; C052387:cocoa butter; D005167:Factor VII; D005340:Fibrinogen; D015942:Factor VIIa; D010959:Tissue Plasminogen Activator